Literature DB >> 7499105

Hepsulfam distribution in blood, plasma and cerebrospinal fluid of baboons.

M V Marshall1, K D Carey, D D Von Hoff, J G Kuhn.   

Abstract

The alkylating agent Hepsulfam (Sulfamic acid 1,7-heptanediyl ester, NSC 329680) was developed as a more hydrophilic analog of busulfan. The objective of this study was to determine partitioning of hepsulfam between blood, plasma, and cerebrospinal fluid (CSF) in two female baboons following intravenous administration. Hepsulfam was administered at 11 mg/kg, and blood and CSF levels were determined by gas chromatography with electron capture detection. Blood levels were fairly constant between animals (17-25 and 20-23 micrograms/ml) for six hours after administration, following peak levels of 43 and 33 micrograms/ml, respectively, for the two animals. Peak plasma levels of 35 and 36 micrograms/ml were achieved, and initial plasma half-lives in baboons were similar to those seen in other species, with a t1/2 alpha of 1 h. The plasma terminal half life of 0.2 h, estimated from limited sampling times, was shorter in baboons than in mice, dogs, or humans. Baboon CSF levels decreased from 1.7 to 0.3 micrograms/ml during 6 h post infusion, and peak concentrations in CSF lagged behind plasma levels. CSF/plasma ratios ranged from 0.33 to 0.62 in one animal, whereas ratios of 0.2-0.25 were maintained in the other animal during the same period. Results from this study indicate hepsulfam will enter the CSF following intravenous administration, and the CSF/plasma ratios are lower than those obtained following oral busulfan administration.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7499105     DOI: 10.1007/bf02614217

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  18 in total

1.  Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy.

Authors:  M Hassan; H Ehrsson; B Smedmyr; T Tötterman; I Wallin; G Oberg; B Simonsson
Journal:  Bone Marrow Transplant       Date:  1989-01       Impact factor: 5.483

2.  Gas chromatographic-mass spectrometric assay for busulfan in biological fluids using a deuterated internal standard.

Authors:  G Vassal; M Re; A Gouyette
Journal:  J Chromatogr       Date:  1988-07-15

3.  Metabolic fate of tritiated busulfan in man.

Authors:  H Vodopick; H E Hamilton; H L Jackson; C T Peng; R F Sheets
Journal:  J Lab Clin Med       Date:  1969-02

4.  Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study.

Authors:  G Vassal; A Deroussent; O Hartmann; D Challine; E Benhamou; D Valteau-Couanet; L Brugières; C Kalifa; A Gouyette; J Lemerle
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

5.  In vitro studies on the mechanism of action of hepsulfam in chronic myelogenous leukemia patients.

Authors:  J R Hincks; A Adlakha; C A Cook; C S Johnson; P Furmanski; N W Gibson
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

6.  Phase I and pharmacokinetic study of hepsulfam (NSC 329680).

Authors:  C B Hendricks; L B Grochow; E K Rowinsky; A A Forastiere; W P McGuire; D S Ettinger; S Sartorius; B Lubejko; R C Donehower
Journal:  Cancer Res       Date:  1991-11-01       Impact factor: 12.701

7.  Gas chromatographic assay for the new antitumor agent sulfamic acid diester (NSC 329680) and its stability in buffer, blood and plasma.

Authors:  J I Brodfuehrer; G Powis
Journal:  J Chromatogr       Date:  1988-06-03

8.  Pharmacokinetic and metabolic studies of high-dose busulphan in adults.

Authors:  M Hassan; G Oberg; H Ehrsson; M Ehrnebo; I Wallin; B Smedmyr; T Tötterman; S Eksborg; B Simonsson
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

9.  Toxicological review of busulfan (Myleran).

Authors:  J B Bishop; J S Wassom
Journal:  Mutat Res       Date:  1986-07       Impact factor: 2.433

10.  Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide.

Authors:  G W Santos; P J Tutschka; R Brookmeyer; R Saral; W E Beschorner; W B Bias; H G Braine; W H Burns; G J Elfenbein; H Kaizer
Journal:  N Engl J Med       Date:  1983-12-01       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.